Neurotech International Ltd. (AU:NTI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International Ltd has appointed the respected Associate Professor Carolyn Ellaway as its new Chief Medical Officer, effective from August 1, 2024. A/Prof Ellaway, recognized for her work in paediatric genetics and her role in the successful Phase I/II Rett Syndrome clinical trial, will lead regulatory and clinical trial strategies for NTI164, a promising drug for paediatric neurological disorders. Neurotech is advancing NTI164, which has shown significant potential in clinical trials for conditions like Autism Spectrum Disorder and Rett Syndrome, and is preparing for a trial in spastic cerebral palsy.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.